{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:13:59Z","timestamp":1785464039115,"version":"3.56.0"},"reference-count":13,"publisher":"Akademiai Kiado Zrt.","issue":"18","license":[{"start":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T00:00:00Z","timestamp":1683417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,5,7]]},"abstract":"<jats:p>A T2-es endot\u00edpussal jellemezhet\u0151 k\u00e9toldali, orrpolyposissal j\u00e1r\u00f3 kr\u00f3nikus\n                    rhinosinusitis nehezen kezelhet\u0151, a konvencion\u00e1lis gy\u00f3gyszeres \u00e9s m\u0171t\u00e9ti\n                    ter\u00e1pi\u00e1ra rezisztens form\u00e1ja tart\u00f3san nem kontroll\u00e1lt t\u00fcnetekkel j\u00e1r egy\u00fctt. A\n                    p\u00e1ciensek \u00e9letmin\u0151s\u00e9ge, napi aktivit\u00e1sa \u00e9s alv\u00e1smin\u0151s\u00e9ge tart\u00f3san \u00e9s s\u00falyos\n                    fokban k\u00e1rosodott. Az elm\u00falt \u00e9vtizedek t\u00fcneti, k\u00f3roki, m\u0171t\u00e9ti, \u00e1ltal\u00e1nos\n                    gyullad\u00e1scs\u00f6kkent\u0151 (sziszt\u00e9m\u00e1s szteroid) kezel\u00e9si form\u00e1i nem ny\u00fajtottak kell\u0151en\n                    hat\u00e9kony megold\u00e1st a refrakter kr\u00f3nikus rhinosinusitis kezel\u00e9s\u00e9ben. A\n                    meghat\u00e1roz\u00f3 effektorsejteket \u00e9s medi\u00e1tormolekul\u00e1kat blokkol\u00f3 humaniz\u00e1lt\n                    monoklon\u00e1lis antitest-ter\u00e1pia min\u0151s\u00e9gi javul\u00e1st eredm\u00e9nyezett ezen a ter\u00fcleten.\n                    A biol\u00f3giai ter\u00e1pia a t\u00f6bbi T2-es szervi manifeszt\u00e1ci\u00f3t is kiv\u00e1l\u00f3an\n                    befoly\u00e1solja, \u00edgy tov\u00e1bbi \u00e9letmin\u0151s\u00e9g-javul\u00e1st jelent, \u00e9s egyben k\u00f6lts\u00e9ghat\u00e9kony\n                    elj\u00e1r\u00e1s. A szerz\u0151 \u00f6sszefoglalja a patogenetikai \u00e9s klinikai alapismereteket, az\n                    el\u00e9rhet\u0151 \u00e9s indik\u00e1lt biol\u00f3giai gy\u00f3gyszereket, a leg\u00fajabb ter\u00e1pi\u00e1s evidenci\u00e1kat,\n                    valamint a kezdeti hazai tapasztalatokat. Orv Hetil. 2023; 164(18): 694\u2013701.<\/jats:p>","DOI":"10.1556\/650.2023.32792","type":"journal-article","created":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:10:12Z","timestamp":1683450612000},"page":"694-701","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":2,"title":["Biol\u00f3giai ter\u00e1pia a fels\u0151 l\u00e9g\u00fati gyullad\u00e1sos betegs\u00e9gekben: az endot\u00edpus-alap\u00fa megk\u00f6zel\u00edt\u00e9s a kr\u00f3nikus rhinosinusitis kezel\u00e9s\u00e9ben"],"prefix":"10.1556","volume":"164","author":[{"given":"Andor","family":"Hirschberg","sequence":"first","affiliation":[{"name":"\u00c9szak-K\u00f6z\u00e9p-budai Centrum, \u00daj Szent J\u00e1nos K\u00f3rh\u00e1z \u00e9s Szakrendel\u0151, F\u00fcl-, Orr-, G\u00e9ge-, Fej-Nyak \u00e9s Sz\u00e1jseb\u00e9szeti Oszt\u00e1ly Budapest, Di\u00f3s \u00e1rok 1\u20133., 1125 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1 Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020 (EPOS2020). Rhinology 2020; 58(Suppl 29): 1-464.","DOI":"10.4193\/Rhin20.401"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/00005537-200301000-00022","article-title":"The pathogenesis of nasal polyposis by immunoglobulin E and interleukin-5 is completed by transforming growth factor-beta1","volume":"113","author":"2 Hirschberg","year":"2003","unstructured":"2 Hirschberg A, J\u00f3k\u00fati A, Darvas Zs, et al. The pathogenesis of nasal polyposis by immunoglobulin E and interleukin-5 is completed by transforming growth factor-beta1. Laryngoscope 2003; 113: 120-124.","journal-title":"Laryngoscope"},{"key":"ref2","unstructured":"3 Hirschberg A, T\u00f3th L, Helfferich F, et al. Indications of biologics and methodology of patient's follow-up in bilateral diffuse nasal polyposis fenotype of chronic rhinosinusitis. Position paper of the Otolaryngological Section of the Hungarian Professional Medical College. [A biol\u00f3giai kezel\u00e9s indik\u00e1ci\u00f3i \u00e9s a betegk\u00f6vet\u00e9s m\u00f3dszertana a kr\u00f3nikus rhinosinusitis k\u00e9toldali, diff\u00faz orrpolip\u00f3zissal k\u00eds\u00e9rt fenot\u00edpus\u00e1ban.] Az Eg\u00e9szs\u00e9g\u00fcgyi Szakmai Koll\u00e9gium F\u00fcl-Orr-G\u00e9g\u00e9szeti Tagozat\u00e1nak szakmai \u00e1ll\u00e1sfoglal\u00e1sa. F\u00fcl-Orr-G\u00e9gegy\u00f3gy. 2021; 67: 55-60. [Hungarian]"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"4 Gevaert","year":"2011","unstructured":"4 Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011; 128: 989-995.","journal-title":"J Allergy Clin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017; 140: 1024-1031.e14.","DOI":"10.1016\/j.jaci.2017.05.044"},{"key":"ref5","unstructured":"6 Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 9: 1141-1153."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022; 149: 1309-1317.e12.","DOI":"10.1016\/j.jaci.2021.08.030"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal interleukin-5 levels determine the response to anti-interleukin-5 treatment in nasal polyp patients","volume":"118","author":"8 Gevaert","year":"2006","unstructured":"8 Gevaert P, Lang-Loidolt D, Stammberger H, et al. Nasal interleukin-5 levels determine the response to anti-interleukin-5 treatment in nasal polyp patients. J Allerg Clin Immunol. 2006; 118: 1133-1141.","journal-title":"J Allerg Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allerg Clin Immunol. 2013; 131: 110-116.e1.","DOI":"10.1016\/j.jaci.2012.07.047"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"10 Gevaert","year":"2020","unstructured":"10 Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020; 146: 595-605.","journal-title":"J Allergy Clin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"11 Bachert","year":"2016","unstructured":"11 Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016; 315: 469-479.","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"12 Bachert","year":"2019","unstructured":"12 Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394: 1638-1650.","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"13 Oykhman","year":"2022","unstructured":"13 Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol. 2022; 149: 1286-1295.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/18\/article-p694.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/18\/article-p694.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/18\/article-p694.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T08:03:10Z","timestamp":1698134590000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/18\/article-p694.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,7]]},"references-count":13,"journal-issue":{"issue":"18"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32792","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,7]]}}}